The study examined the safety and tolerability of Bemdaneprocel in Parkinson's patients over a period of two years. The results showed that the transplanted cells continued to survive and grow in the brain even after the twelve-month immunosuppression was discontinued. No adverse events related to the cell therapy were reported, Bayer and Bluerock stated on Friday.

The completed study shows that the transplanted cells survive and there are initial signs that Bemdaneprocel may help patients better control their motor symptoms," explained Dr. Claire Henchcliffe, principal investigator and neurologist at the University of California. "This could be an important advancement in the treatment of Parkinson's.

The exact data is to be presented at the International Parkinson Congress in Philadelphia over the weekend. BlueRock's bemdaneprocel is currently the most advanced cell therapy for Parkinson's patients in the USA and could represent a significant expansion of existing treatment options.

The study and the associated hope for an effective Parkinson's therapy have positively influenced Bayer's stock price. Bayer shares temporarily rose by 3.21 percent and traded at 30.05 euros on XETRA on Friday.

Bluerock, a subsidiary of Bayer, focuses on the development of novel cell therapies for the treatment of neurological diseases. Bemdaneprocel uses human dopaminergic neurons derived from stem cells to repair brain damage caused by Parkinson's disease and restore dopamine production. This could enable affected individuals to better control their motor functions and significantly improve their quality of life.

With Bemdaneprocel, Bayer could achieve a significant breakthrough in the field of regenerative medicine. The next steps will now be the detailed analysis of the study results and the preparation of larger clinical trials, which are necessary to further confirm efficacy and safety.